The World Health Organization offers that in 2020, there were 2.3 million women diagnosed with breast cancer and 685,000 deaths globally. As of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past five years, making it the world’s most prevalent cancer.

According to the American Cancer Society, there were an estimated 287,850 new cases of invasive breast cancer among women in the USA in 2022. In addition, 43,250 women died from the disease.

An estimated 51,400 cases of non-invasive ductal carcinoma in situ (DCIS) will be diagnosed among women. Although breast cancer is predominantly female, approximately 2,710 new cases and 530 deaths (about 1% of all breast cancer cases and deaths) will occur among men.

Fortunately, most individuals with early breast cancer become long-term survivors, according to new British research that finds a substantial reduction in the risk of death since the 1990s.

First, though, I want to explore the fascinating history of breast cancer. We begin in ancient Egypt.

Breast Cancer — Ancient History

Breast cancer has a long and complex history that spans centuries. Understanding and managing breast cancer has evolved significantly, improving diagnosis and survival rates.

Breast cancer has been documented since ancient Egypt, around 1600 BCE. The Edwin Smith Papyrus, an Egyptian medical text, mentioned a condition characterized by bulging tumors in the breast.

The treatment options during this time included cauterization or completely removing the affected breast.

Classical Antiquity

During the classical period, the Greek physician Hippocrates (460–370 BCE) referred to breast cancer as “karkinos” and described the spread of the disease to nearby lymph nodes.

He proposed that an imbalance of bodily fluids caused breast cancer. Surgical intervention was still the primary treatment, involving radical mastectomy or acidic substances to destroy the tumor.

Middle Ages

In the Middle Ages, breast cancer was often associated with superstitions and mysticism. It was believed to be caused by supernatural forces or punishment for immoral behavior.

Treatments included various herbal remedies, poultices, and even incantations. Surgery was rare and generally not recommended due to the high risk of infection.

Renaissance and Enlightenment.

During the Renaissance, medical knowledge and understanding of breast cancer advanced.

In the 16th century, French surgeon Ambroise Paré introduced a less invasive method of surgery called the “horizontal incision,” which spared the chest wall muscles. This technique reduced complications and improved outcomes for patients.

Breast Cancer in the 1700s and 1800s

18th and 19th Centuries

The 18th and 19th centuries witnessed significant progress in understanding breast cancer.

In 1775, the Scottish surgeon Benjamin Bell advocated for early diagnosis and surgical intervention, recommending lumpectomy (partial breast removal) instead of radical mastectomy. However, many surgeons still favored aggressive procedures.

In the 19th century, advances in anesthesia and aseptic techniques improved surgical outcomes. William Stewart Halsted, an American surgeon, introduced radical mastectomy in the 1880s, which involved removing the entire breast, underlying chest muscles, and axillary lymph nodes.

Radical mastectomy became the standard treatment for several decades despite its physical and psychological impact on patients.

Breast Cancer in the 1900s

20th Century

The 20th century brought further advancements in breast cancer research and treatment. In the 1940s, the use of X-rays for diagnostic purposes became widespread. This development led to mammography in the 1960s, revolutionizing early detection and screening efforts.

In the 1970s, the discovery of estrogen receptors in breast cancer cells led to the development of hormone therapies. Tamoxifen, a selective estrogen receptor modulator, became the first FDA-approved drug for breast cancer treatment in 1977.

Advances in imaging technologies, such as ultrasound and magnetic resonance imaging (MRI), provided additional tools for diagnosing and staging breast cancer.

In the 1980s, fine-needle aspiration biopsy allowed for less invasive and more accurate diagnosis.

Recent Advances in Breast Cancer Management

The 21st century brought significant progress in understanding the genetics of breast cancer. The discovery of BRCA1 and BRCA2 genes, which increase the risk of developing breast and ovarian cancer, provided valuable insights into the hereditary component of the disease.

Genetic testing and counseling have become important tools for risk assessment and personalized treatment planning.

Targeted therapies, such as Herceptin (trastuzumab), were developed to target breast cancer cells that overexpress the HER2 protein specifically. These treatments have shown remarkable efficacy, improving survival rates for HER2-positive breast cancer patients.

Surgery advances

Furthermore, advancements in surgical techniques, including breast-conserving (lumpectomy) and oncoplastic surgery, have improved cosmetic outcomes while ensuring effective cancer removal.

Today, breast cancer research continues to focus on personalized medicine, immunotherapies, targeted therapies, and early detection methods.

Public awareness

Public awareness campaigns and improved access to screening have contributed to earlier diagnoses and improved survival rates for breast cancer patients.

While breast cancer remains a significant health challenge, the ongoing efforts of researchers, healthcare professionals, and advocacy organizations are steadily advancing our understanding and treatment of this disease.

Breast Cancer is Common

Breast cancer remains a significant concern for women worldwide, impacting millions of lives annually.

Did you know women lose more disability-adjusted years to breast cancer than any other cancer type? Breast cancer occurs in every country and women (and, far less commonly, men) at virtually any age.

Most with breast cancer are diagnosed after puberty but with increasing rates in later life.

There was little change in breast cancer mortality from the 1930s through the 1970s. Fortunately, early detection programs combined with improved management tools led to survival improvements beginning in the 1980s.

However, recent research has brought forth an encouraging revelation: the vast majority of women diagnosed with early-stage breast cancer are likely to become long-term survivors.

This finding offers hope and underscores the tremendous progress in understanding, diagnosing, and treating breast cancer. Let’s explore the implications of this discovery, highlighting the key factors contributing to improved survival rates and the importance of continued research and support for breast cancer patients.

Breast Cancer Survival Rates Rising

Breast cancer treatment has witnessed remarkable advancements in recent decades, significantly improving the prognosis for patients.

The advent of early detection through widespread mammography screening programs has played a crucial role in identifying breast cancer at its nascent stages, enabling timely intervention and treatment. As a result, most breast cancer cases diagnosed today are at an early stage, where the tumor is confined to the breast or nearby lymph nodes.

Treatment modalities have evolved significantly in conjunction with early detection, incorporating a multidisciplinary approach tailored to each patient’s unique circumstances.

Surgery, radiation therapy, chemotherapy, targeted therapies, and hormone therapy are among the arsenal of treatments employed in breast cancer management. The personalized nature of these treatments ensures that patients receive the most appropriate interventions based on the characteristics of their cancer, such as hormone receptor status, HER2 status, and genetic mutations.

Research Fuels Breast Cancer Advances

The progress achieved in breast cancer treatment owes much to ongoing research and clinical trials. Scientists and medical professionals continuously strive to unravel the intricacies of breast cancer biology, leading to the development of novel therapeutic strategies and precision medicine approaches.

Clinical trials provide a platform for testing innovative treatment modalities, ensuring patients receive the most cutting-edge care. By participating in clinical trials, women with early breast cancer contribute to expanding the body of knowledge and improving outcomes for future generations.

Prognostic Factors for Survival

Various factors influence the prognosis for women diagnosed with early breast cancer. Several clinical and biological indicators are considered to predict the likelihood of long-term survival.

These include the following:

• Size and grade of the tumor
• Lymph node involvement
• Hormone receptor status
• HER2/neu overexpression
• Specific genetic mutations.

Determining these factors assists clinicians in devising optimal management plans and tailoring interventions based on individual patient needs.

Moreover, advancements in molecular diagnostics have led to the emergence of gene expression profiling tests, such as Oncotype DX and Mammaprint.

These tests analyze the activity of specific genes within the tumor and provide valuable information on the likelihood of disease recurrence and the potential benefit from chemotherapy.

By utilizing these predictive tools, healthcare providers can guide patients toward the most appropriate treatment decisions, reducing unnecessary interventions and focusing on therapies with proven efficacy.

Good News From a New Study

Receiving a breast cancer diagnosis can be devastating. Fortunately, most individuals diagnosed with early breast cancer become long-term survivors. That’s the finding of a new study in the British Medical Journal that reports the following:

There has been a substantial reduction in the risk of death since the 1990s.

The news is reassuring as a radiation oncologist specializing in breast cancer. The findings are also good news for most early breast cancer patients.

In the late 1900s, the average risk of dying from breast cancer (within five years of diagnosis) was 14 percent. Today, it has dropped to five percent. More than six in ten women diagnosed from 2010 through 2015 had a five-year risk of three percent or less.

The study authors analyzed National Cancer Registration and Analysis Service data for over 512,000 women diagnosed in England with early breast cancer between January 1993 and December 2015.

Early breast cancer is defined as confined to the breast or spreading only to the underarm (axillary) lymph nodes.

Breast Cancer: We Still Have Work to Do

The risk of breast cancer-related death was under three percent for nearly two-thirds (63 percent) of women, but it was over 20 percent for five percent.

While the increasing survival rates for women with early breast cancer offer tremendous hope, it is essential to acknowledge the psychosocial aspects of the disease.

Breast cancer diagnosis and treatment can profoundly impact a woman’s woman’s well-being, body image, and overall quality of life. Therefore, providing comprehensive psychosocial support to the patient’s crucial.

Supportive care programs, survivorship initiatives, and counseling services are vital in addressing breast cancer survivors and their psychological needs. These programs facilitate the adjustment to life after cancer treatment, helping individuals cope with anxiety, depression, and body image concerns.

By fostering a holistic approach to care, healthcare providers can empower survivors to embrace their new normal and live fulfilling lives beyond their breast cancer diagnosis.

Continued Research and Awareness are Key

While the latest findings on long-term survival rates in early breast cancer cause celebration, it is imperative to remember that breast cancer remains a significant global health challenge.

Continued research is vital to unravel the complexities of the disease, identify new therapeutic targets, and improve treatment outcomes for all patients. Robust support for breast cancer research initiatives and awareness campaigns is necessary to maintain the momentum in the fight against this formidable adversary.

Key points — A Triumph of Science: Breast Cancer Survival

Question. Can most women with early breast cancer expect to become long-term survivors? How much has survival improved recently?

Findings. In the late 1900s, the average risk of dying from breast cancer (within five years of diagnosis) was 14 percent. Today, it has dropped to five percent. More than six in ten women diagnosed from 2010 through 2015 had a five-year risk of three percent or less.

The study has its challenges. The findings were observational and can’t elucidate the causes of these reductions in death rates. Information on cancer recurrence was not available.

Another limitation is the current report focused on patients initially treated with surgery, not those treated with drugs (such as chemotherapy or anti-HER2 medicines) to reduce the size of their cancer before surgery or those whose cancer had already spread.

Final Thoughts: Breast Cancer Survival

Improved survival rates are likely the combination of early detection through mammography screening programs, advancements in management, personalized medicine approaches, and the contributions of bench research and clinical trials.

Meaning. Fortunately, most individuals with early breast cancer become long-term survivors, according to new British research that finds a substantial reduction in the risk of death since the 1990s.

The risk of breast cancer-related death is now under three percent for nearly two-thirds (63 percent) of women, but it was over 20 percent for five percent. We have made great progress, but we have much to do.

Improved survival rates can be attributed to early detection through mammography screening programs, advancements in treatment modalities, personalized medicine approaches, and the contributions of research and clinical trials.

The post A Triumph of Science: Breast Cancer Survival appeared first on Medika Life.

Moreover, this rise coincides with a four to five percent annual increase in advanced-stage prostate cancer diagnoses since 2011; the proportion of men diagnosed with distant spread of cancer (metastases) doubled.

I am concerned each day as we continue to see an increasing proportion of men with more advanced prostate cancer in my oncology clinic. Today, I want to focus on seven ways men can reduce their risk of getting (or dying from) prostate cancer.

Men need to be aware of the health of their bodies, as well — prostate cancer and breast cancer are almost on the same level. It’s fascinating that the correlation between the two is almost the same — people don’t talk about it so much, but they are almost equal in numbers. — Olivia Newton-John

Let’s look at seven ways men can drop their prostate cancer risk.

1. Dropping prostate cancer risk through diet

While we don’t fully understand the relationship between diet and prostate cancer risk, studies suggest that certain eating habits may be beneficial.

• Reduce fat intake. Eat less trans and saturated fats. Incorporate healthy fats such as omega-3 fatty acids from fish, nuts, and seeds into your diet.
• Eat more fruits and vegetables. Consume a wide variety of produce, including lots of leafy greens. The antioxidant lycopene in cooked or processed tomatoes may slow prostate cancer cell growth. Cruciferous vegetables (for example, cauliflower and broccoli) contain sulforaphane, which may reduce cancer risk.

• Consider soy and green tea. Some clinical studies hint that soy can lower a measure of prostate cancer activity (prostate-specific antigen or PSA). Green tea consumption may help men at higher risk for prostate cancer.
• Avoid charred meat. The charred meat (from grilling or frying at high temperatures) may produce chemical compounds associated with cancer.

2. Drop prostate cancer risk through exercise

Harvard Chan School scientists study homed in on a common molecular alteration in prostate tumors called TMPRSS2:ERG. This gene fusion occurs in about one-half of prostate cancers. The study showed for the first time that long-term vigorous physical activity is associated with a lower risk of developing TMPRSS2:ERG-positive prostate cancers.3. Stop Smoking and

3. Drink Less and don’t smoke

Quitting smoking lowers cancer risk. For those who enjoy alcohol, please consider doing so in moderation. The Prostate Cancer Foundation offers this chill observation: You can safely have one daily drink.

4. Drop prostate cancer risk: Stay sexually active

Men with a higher frequency of ejaculation (with or without a sexual partner) are less likely to be diagnosed with prostate cancer.

For example, a 2016 Harvard study discovered that ejaculating over 20 times monthly reduced prostate cancer risk by about one-fifth compared to ejaculating only four to seven times per month for men in their 20s and 40s, respectively.

While investigations continue, some experts postulate that ejaculation clears the body of toxins and other substances that could cause inflammation.

5. Maintain a Healthy Weight

The American Cancer Society offers that obesity is a risk factor for developing more aggressive prostate cancer. Maintaining a healthy weight as you age can reduce your cancer risk and many other health problems.

6. Family history

While prostate cancer runs in some families, most cases occur in men with no history of the disease. Still, having a father or brother with prostate cancer doubles a man’s risk (higher if you have a brother with it than a father). Having several affected relatives further increase risk, especially if the relatives were young at diagnosis.

Inherited mutations in BRCA1 or BRCA2 (breast cancer genes 1 and 2) increase prostate cancer risk in men. Men with Lynch syndrome (hereditary non-polyposis colorectal cancer) have a higher risk of numerous cancers, including prostate cancer. Other inherited gene changes can also raise risk: What Causes Prostate Cancer?

7. Get appropriate screening

The American Cancer Society (ACS) recommends that men have a chance to make an informed decision with their healthcare provider about whether to have prostate cancer screening. The decision should be made after getting information about the uncertainties, risks, and potential benefits of prostate cancer screening.

The discussion about screening should take place at:

• Age 50 for men with an average risk of prostate cancer and a life expectancy of at least ten years.
• Age 45 for men at high risk of developing prostate cancer. The high-risk group includes African Americans and men who have a first-degree relative (father or brother) diagnosed with prostate cancer at an early age (younger than age 65).
• Age 40 for men at even higher risk (those with more than one first-degree relative who had prostate cancer at an early age).

Two more quick observations: Some studies suggest good vitamin D levels are associated with a lower risk of prostate cancer. There is some evidence that firefighters exposed to certain chemicals might have a higher risk of prostate cancer.

The post 7 Tips to Lower Your Prostate Cancer Risk — Using Lifestyle and Screening appeared first on Medika Life.